Literature DB >> 16671077

Cardiac 123I-MIBG scintigraphy in patients with essential tremor.

Phil Hyu Lee1, Ji Won Kim, Oh Young Bang, In Soo Joo, Seok-Nam Yoon, Kyoon Huh.   

Abstract

In some cases, it is difficult to differentiate essential tremor (ET) from Parkinson's disease (PD), especially in the early stages of the disease. We investigated cardiac sympathetic dysfunction using (123)I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy in 22 patients with ET, in comparison with early PD and tremor-dominant PD (TDPD). The mean ratio of (123)I-MIBG uptake in the region of interest in the heart to that in the mediastinum (H/M ratio) was significantly greater in patients with ET (1.99 +/- 0.21) than in those with either TDPD (1.28 +/- 0.11) or early PD (1.28 +/- 0.17; each P < 0.001). The H/M ratio in all patients with ET was greater than two standard deviations above the range of the ratio in the patients with early PD or TDPD. (c) 2006 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16671077     DOI: 10.1002/mds.20908

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  10 in total

1.  Cardiovascular autonomic dysfunctions in elderly patients with essential tremor: comparison with healthy controls.

Authors:  Joong-Seok Kim; Yoon-Sang Oh; Hyung-Eun Park; Si-Hoon Lee; Jeong-Wook Park; In-Uk Song; Jae-Young An; Hun-Jun Park; Byung-Chul Son; Kwang-Soo Lee
Journal:  Neurol Sci       Date:  2016-01-04       Impact factor: 3.307

Review 2.  MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis.

Authors:  Giorgio Treglia; Ernesto Cason; Antonella Stefanelli; Fabrizio Cocciolillo; Daniela Di Giuda; Giorgio Fagioli; Alessandro Giordano
Journal:  Clin Auton Res       Date:  2011-07-27       Impact factor: 4.435

Review 3.  Recent developments in innervation imaging using iodine-123-metaiodobenzylguanidine scintigraphy in Lewy body diseases.

Authors:  Giorgio Treglia; Ernesto Cason; Anna Gabellini; Alessandro Giordano; Giorgio Fagioli
Journal:  Neurol Sci       Date:  2010-03-10       Impact factor: 3.307

4.  Myocardial MIBG scintigraphy: a useful clinical tool? : A retrospective study in 50 parkinsonian patients.

Authors:  Ines Fröhlich; Wilfried Pilloy; Michel Vaillant; Nico J Diederich
Journal:  Neurol Sci       Date:  2010-02-13       Impact factor: 3.307

Review 5.  Role of Neuroimaging on Differentiation of Parkinson's Disease and Its Related Diseases.

Authors:  Toshihide Ogawa; Shinya Fujii; Keita Kuya; Shin-Ichiro Kitao; Yuki Shinohara; Mana Ishibashi; Yoshio Tanabe
Journal:  Yonago Acta Med       Date:  2018-09-26       Impact factor: 1.641

6.  123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder.

Authors:  Tomoyuki Miyamoto; Masayuki Miyamoto; Keisuke Suzuki; Momoka Nishibayashi; Masaoki Iwanami; Koichi Hirata
Journal:  Sleep       Date:  2008-05       Impact factor: 5.849

7.  The Utility of Segmental Analysis in Cardiac I-123 MIBG SPECT in Parkinson's Disease.

Authors:  Soo Hyun Kwon; Joon-Kee Yoon; Jung Han Yoon; Su Jin Lee; Kyung Sook Jo; Dong Hyun Lee; Young-Sil An
Journal:  Nucl Med Mol Imaging       Date:  2015-07-28

8.  Diagnostic and Pathophysiological Impact of Myocardial MIBG Scintigraphy in Parkinson's Disease.

Authors:  Jörg Spiegel
Journal:  Parkinsons Dis       Date:  2009-12-22

Review 9.  (123)I-Metaiodobenzylguanidine Myocardial Scintigraphy in Lewy Body-Related Disorders: A Literature Review.

Authors:  Eun Joo Chung; Sang Jin Kim
Journal:  J Mov Disord       Date:  2015-05-31

10.  REM-Sleep Behavior Disorder in Patients With Essential Tremor: What Is Its Clinical Significance?

Authors:  Maria Salsone; Gennarina Arabia; Lucia Manfredini; Andrea Quattrone; Carmelina Chiriaco; Basilio Vescio; Miriam Sturniolo; Maurizio Morelli; Rita Nistico'; Fabiana Novellino; Antonio Gambardella; Aldo Quattrone
Journal:  Front Neurol       Date:  2019-04-24       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.